Selected Ref. | MDS n (%) | CMML n (%) | MPN n (%) | Secondary AML n (%) | De novo AML n (%) |
---|---|---|---|---|---|
*Abdel-Wahab et al., [25] | Â | Â | Â | 12/63 (19.3) | Â |
*Abdel-Wahab et al., [18] | Â | 3/24 (12.5) | 3/46 PMF (6.5) | Â | Â |
BĂ©jar et al., [21] | 63/439 (14.4) | Â | Â | Â | Â |
Brecqueville et al., [26] | Â | Â | 17/149 (11.4): 6/30 PMF (20), 2/30 PV (7), 2/53 ET (4), | Â | Â |
Boultwood et al., [5] | 28/182 (15.4) | 17/51 (33.3) | Â | 9/40 (22.5) | 8/27 (29.6) |
Boultwood et al., [27] | Â | Â | +6/41 (CML) (14.6) | Â | Â |
Carbuccia et al., [28] | Â | Â | 5/64 (7.8) | Â | Â |
Carbuccia et al., [20] | Â | Â | Â | 9/17 (58) | 3/46 (6) |
Chou et al., [29] | Â | Â | Â | Â | 54/501 (10.8) |
Gelsi-Boyer et al., [1] | 4/35 (11.4) | 17/39 (43.6) | Â | Â | Â |
Gelsi-Boyer et al., [30] | Â | 25/53 (47.2) | Â | Â | Â |
Grossmann et al., [31] | Â | 41/79 (52) | Â | Â | Â |
Jankowsa et al.,[32] | Â | 24/52 (46) | Â | Â | Â |
Pratcorona et al., [33] | Â | Â | Â | 3/24 (12.5) | 35/775 (4.5) |
Ricci et al.,[34] | Â | Â | 23/42 PMF (54.8) | Â | Â |
Rocquain et al., [22] | 13/65 (20) | Â | Â | 9/18 (50) | 3/46 (6.5) |
Shen et al., [35] | Â | Â | Â | Â | 27/605 (4.5) |
Stein et al., [36] | Â | Â | 12/47 PMF (25.5) 1/42 PV (2) | Â | Â |
Thol et al., [37] | 40/193 (20.7) | Â | Â | Â | Â |
Total* | 148/914 (16.2) | 124/274 (45) | 41/119 PMF (34.5) | 30/99 (30.3) | 130/2000 (6.5) |